Elicio Therapeutics, Inc. (ELTX) News
Follow Elicio Therapeutics, Inc. (ELTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Elicio Therapeutics 3Q 2026: EPS ($0.3) — 10-Q Summary
Elicio Therapeutics’ net loss narrowed year over year in the third quarter, as lower clinical-trial costs and a gain from changes in warrant fair value more than offset higher personnel and professional fees.Financial Hi
EARNINGS | Nov 05, 2026, 09:29 PM UTC
M
Elicio Therapeutics Phase 2 Trial Misses Primary DFS Endpoint
Elicio Therapeutics said its Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P) did not meet the ITT primary DFS endpoint (HR 0.85). The company cited a baseline ctDNA imbalance and plans to discuss a refined Phase 3 s
EQUITY | Oct 23, 2026, 01:04 PM UTC
L
Elicio Therapeutics Price Target Cut to $8.00/Share From $27.00 by B. Riley Securities
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 02:26 PM UTC
H
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. NASDAQ:ELTX (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, tod
GEOPOLITICS | Sep 24, 2026, 12:03 PM UTC
L
ELTX: ELI-002 immunotherapy shows strong early results and is advancing to new combination trials in KRAS cancers
The discussion highlighted advances in lymph node-targeted immunotherapy, with ELI-002 showing promising responses in metastatic pancreatic cancer and a strong safety profile. Upcoming trials will combine ELI-002 with RA
NEWS | Sep 14, 2026, 09:49 PM UTC
L
ELTX: ELI-002 immunotherapy shows strong early results in KRAS cancers, with new trials starting soon
The company is advancing lymph node-targeted immunotherapies, with ELI-002 showing promising responses in KRAS-mutant cancers and plans for a new phase I trial in metastatic pancreatic cancer. The platform's modularity s
NEWS | Sep 14, 2026, 09:31 PM UTC
L
Elicio Therapeutics reports Q2 2026 financial results, provides corporate updates
Elicio Therapeutics (ELTX) reports its second-quarter 2026 financial results and provides corporate updates, according to the TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
L
Elicio Therapeutics shares are trading lower after the company announced the pricing of its $15 million offering of 4,380,313 shares.
Elicio Therapeutics shares are trading lower after the company announced the pricing of its $15 million offering of 4,380,313 shares.
EQUITY | Jul 02, 2026, 11:52 AM UTC
L
Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In
Elicio Therapeutics Prices $15M Registered Direct Offering Of 4,380,313 Common Shares, Proceeds To Fund Phase 1 Development Of ELI-002 7P In Metastatic PDAC
EQUITY | Jul 02, 2026, 06:26 AM UTC